These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25076342)

  • 21. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
    Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
    Fujitani K
    Dig Surg; 2013; 30(2):119-29. PubMed ID: 23867588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Li J; Saif MW
    JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
    Boeck S; Bruns CJ; Sargent M; Schafer C; Seufferlein T; Jauch KW; Heinemann V
    Oncology; 2009; 77(1):40-8. PubMed ID: 19556808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
    Lind PA; Isaksson B; Almström M; Johnsson A; Albiin N; Byström P; Permert J
    Acta Oncol; 2008; 47(3):413-20. PubMed ID: 17882555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant
    Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
    Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?
    Xia BT; Fu B; Wang J; Kim Y; Ahmad SA; Dhar VK; Levinsky NC; Hanseman DJ; Habib DA; Wilson GC; Smith M; Olowokure OO; Kharofa J; Al Humaidi AH; Choe KA; Abbott DE; Ahmad SA
    J Surg Oncol; 2017 Mar; 115(4):376-383. PubMed ID: 28105634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
    Hazard L; Jones K; Shaban A; Anker C; Scaife C; Weis J; Mulvihill S
    J Gastrointest Cancer; 2012 Jun; 43(2):258-66. PubMed ID: 21243531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
    Barrord M; Ahmad S; Patel S; Olowokure O; Sussman J; Smith M; Poreddy S; Esslinger H; Latif T; Choe K; Kharofa J
    Pancreas; 2020 Aug; 49(7):941-946. PubMed ID: 32658077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
    Walma MS; Brada LJ; Patuleia SIS; Blomjous JG; Bollen TL; Bosscha K; Bruijnen RC; Busch OR; Creemers GJ; Daams F; van Dam R; Festen S; Jan de Groot D; Willem de Groot J; Mohammad NH; Hermans JJ; de Hingh IH; Kerver ED; van Leeuwen MS; van der Leij C; Liem MS; van Lienden KP; Los M; de Meijer VE; Meijerink MR; Mekenkamp LJ; Nederend J; Nio CY; Patijn GA; Polée MB; Pruijt JF; Renken NS; Rombouts SJ; Schouten TJ; Stommel MWJ; Verweij ME; de Vos-Geelen J; de Vries JJJ; Vulink A; Wessels FJ; Wilmink JW; van Santvoort HC; Besselink MG; Molenaar IQ;
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):699-707. PubMed ID: 33280952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
    Brown ZJ; Cloyd JM
    J Surg Oncol; 2021 May; 123(6):1432-1440. PubMed ID: 33831253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locally advanced unresectable pancreatic cancer.
    Johung KL; Saif MW; Chang BW
    JOP; 2014 Jul; 15(4):329-31. PubMed ID: 25076335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic Cancer in the Era of Neoadjuvant Therapy: A Narrative Overview.
    Casciani F; Marchegiani G; Malleo G; Bassi C; Salvia R
    Chirurgia (Bucur); 2018; 113(3):307-317. PubMed ID: 29981662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
    Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
    J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
    Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
    Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.